[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Ma CD, Chen CM, Chen XS, Liu GY, Di GH, Wu J, Lu JS, Yang WT, Chen JY, Shao ZM, Shen ZZ, Shen KW: Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer. Anticancer Res; 2008 Sep-Oct;28(5B):3093-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
  • BACKGROUND: The purpose of this study was to evaluate retrospectively the efficacy and safety of neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patient with locally advanced breast cancer (LABC).
  • PATIENTS AND METHODS: From 2002 to 2006, 14 female elderly patients with LABC underwent neoadjuvant chemotherapy with vinorelbine-containing regimens.
  • All 14 patients received 2-6 cycles of chemotherapy.
  • Six patients had stage IIIA breast tumor, 7 stage IIIB and 1 stage IIIC.
  • CONCLUSION: The results of the current study showed that vinorelbine-containing neoadjuvant chemotherapy was effective and well-tolerated in elderly patients with LABC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031963.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


2. Pölcher M, Rudlowski C, Friedrichs N, Mielich M, Höller T, Wolfgarten M, Kübler K, Büttner R, Kuhn W, Braun M: In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer. BMC Cancer; 2010 Apr 13;10:137
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo intratumor angiogenic treatment effects during taxane-based neoadjuvant chemotherapy of ovarian cancer.
  • BACKGROUND: The aim of our study was to analyze the effect of taxane-based chemotherapy on tumor angiogenesis in patients with advanced epithelial ovarian cancer.
  • METHODS: Within a prospective phase II trial, 32 patients with stage IIIC and IV ovarian cancer were treated with either two or three cycles of neoadjuvant chemotherapy prior to cytoreductive surgery.
  • Changes in intratumor microvessel density (MVD) were assessed with immunohistochemistry by staining pre- and posttreatment surgical tumor specimens with panendothelial, neovascular and lymphatic vessel markers.
  • RESULTS: Mean values of MVD defined by CD31, CD34, CD105 and D2-40 antibodies showed 12.3, 21.0, 2.7 and 3.1 vessels per high power field (HPF) before chemotherapy and increased after treatment to 15.3, 21.8, 4.8 and 3.6 per HPF, respectively.
  • CONCLUSION: Taxane-based chemotherapy appears to promote tumor vascularization when administered every 3 weeks.
  • A possible explanation is the secondary recovery of MVD in response to immediate cytotoxic and antiangiogenic effects of the chemotherapy.
  • If confirmed prospectively, these findings favor shorter treatment intervals of taxane-based chemotherapy to counteract proangiogenic recovery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neovascularization, Pathologic / prevention & control. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / administration & dosage. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Germany. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Microvessels / drug effects. Microvessels / pathology. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Proportional Hazards Models. Prospective Studies. Taxoids / administration & dosage. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):469-74 [19135712.001]
  • [Cites] Histol Histopathol. 2009 Apr;24(4):425-35 [19224445.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):232-9 [19249681.001]
  • [Cites] Oncol Rep. 2009 Sep;22(3):605-13 [19639211.001]
  • [Cites] Lancet. 2009 Oct 17;374(9698):1331-8 [19767092.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):67-73 [11191065.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1195-206 [11181686.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3369-72 [11309294.001]
  • [Cites] Oncogene. 2001 Jun 28;20(29):3806-13 [11439344.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2585-91 [11745193.001]
  • [Cites] Cancer Lett. 2002 Feb 8;176(1):111-8 [11790460.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1255-7 [12218087.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1191-200 [12479700.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):121-9 [12532428.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2843-8 [12807937.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6557-63 [14528280.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):686-90 [14966092.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):639-47 [15270667.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9 [15308462.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):815-23 [15361189.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Ann N Y Acad Sci. 1994 Apr 18;714:165-74 [8017765.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):9-19 [7541613.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Blood. 1996 Jan 1;87(1):1-13 [8547630.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):205-11 [8682589.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):81-6 [8988045.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):587-91 [10100710.001]
  • [Cites] Cancer Lett. 1999 Apr 26;138(1-2):175-82 [10378790.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2433-40 [15781659.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):516-25 [15965493.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9 [16515588.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):835-45 [17036040.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3925-32 [17094423.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):281-8 [17210709.001]
  • [Cites] Wiad Lek. 2007;60(3-4):129-37 [17726864.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5165-71 [18024863.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5180-6 [18024865.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):76-82 [18165643.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):263-73 [18772115.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Feb;69(2):108-24 [18768327.001]
  • [Cites] Cancer Cell. 2009 Mar 3;15(3):220-31 [19249680.001]
  • (PMID = 20388201.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00551577
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2873383
  •  go-up   go-down


3. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA: Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys; 2007 Jul 15;68(4):1004-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
  • PURPOSE: The aim of this study was to investigate the role of postmastectomy radiation therapy in women with breast cancer who achieved a pathologic complete response (pCR) to neoadjuvant chemotherapy.
  • METHODS AND MATERIALS: We retrospectively identified 226 patients treated at our institution who achieved a pCR at surgery after receiving neoadjuvant chemotherapy.
  • Of these, the 106 patients without inflammatory breast cancer who were treated with mastectomy were analyzed.
  • The patients' clinical stages at diagnosis were I in 2%, II in 31%, IIIA in 30%, IIIB in 25%, and IIIC in 11% (American Joint Committee on Cancer 2003 system).
  • Of the patients, 92% received anthracycline-based chemotherapy, and 38% also received a taxane.
  • A total of 72 patients received postmastectomy radiation therapy, and 34 did not.
  • Use of radiation therapy did not affect the 10-year rates of LRR for patients with Stage I or II disease (the 10-year LRR rates were 0% for both groups).
  • However, the 10-year LRR rate for patients with Stage III disease was significantly improved with radiation therapy (7.3% +/- 3.5% with vs. 33.3% +/- 15.7% without; p = 0.040).
  • Within this cohort, use of radiation therapy was also associated with improved disease-specific and overall survival.
  • CONCLUSION: Postmastectomy radiation therapy provides a significant clinical benefit for breast cancer patients who present with clinical Stage III disease and achieve a pCR after neoadjuvant chemotherapy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418973.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA077050; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / L30 CA123630-01; United States / NCI NIH HHS / CA / L30 CA123630-02; United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / T32 CA 77050; United States / NCI NIH HHS / CA / L30 CA123630
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS283616; NLM/ PMC4329732
  •  go-up   go-down


Advertisement
4. Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z, Shen K: Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months. BMC Cancer; 2009;9:375
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.
  • BACKGROUND: This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy (NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at identification of predictive markers for the long-term outcome in noninflammatory locally advanced breast cancer (NLABC).
  • All patients were diagnosed with invasive breast cancer using 14 G core needle biopsy and treated with three cycles of VE before surgery.
  • Local-regional radiotherapy was offered to all patients after the completion of chemotherapy followed by hormonal therapy according to hormone receptor status.
  • Tissue sections cut from formalin-fixed paraffin-embedded blocks from biopsy specimens and postoperative tumor tissues were stained for the presence of estrogen receptor (ER), progesterone receptor (PgR), HER-2 (human epidermal growth factor receptor-2), and MIB-1(Ki-67).
  • RESULTS: Patients characteristics were median age 52 years (range: 25-70 years); clinical TNM stage, stage IIB (n = 32), stage IIIA (n = 56), stage IIIB (n = 22) and stage IIIC (n = 9).
  • Among patients with non-pCR, those with a pathological response at the tumor site with special involvement (i.e. skin, vessel and more than one quadrant) were at a higher risk of disease relapse and death (p < 0.001, p = 0.001, respectively).
  • Pathological response in the tumor site, pre-Ki-67 and post-Ki-67 expression, and pre-ER expression were the important variables that predicted long-term outcome.
  • [MeSH-major] Breast Neoplasms / drug therapy. Epirubicin / administration & dosage. Neoadjuvant Therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. China. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Ki-67 Antigen / genetics. Ki-67 Antigen / metabolism. Middle Aged. Receptors, Estrogen / genetics. Receptors, Estrogen / metabolism. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2385-94 [10856098.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4135-9 [11911307.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):303-7 [12040294.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3628-36 [12202663.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):91-8 [12653672.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4165-74 [14559892.001]
  • [Cites] Breast. 2003 Feb;12(1):42-50 [14659354.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6622-8 [15475452.001]
  • [Cites] N Engl J Med. 1978 Dec 14;299(24):1330-4 [714108.001]
  • [Cites] Cancer. 1980 Dec 15;46(12 Suppl):2829-34 [7448729.001]
  • [Cites] Am Surg. 1996 Feb;62(2):162-5 [8554195.001]
  • [Cites] Anticancer Res. 1996 Sep-Oct;16(5B):3105-10 [8920776.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):621-6 [9484820.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(1):11-20 [9541185.001]
  • [Cites] Breast Cancer Res Treat. 1998 Mar;48(2):107-16 [9596482.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] Clin Ter. 1998 Jan-Feb;149(921):61-74 [9621491.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] J Chemother. 1998 Aug;10(4):326-30 [9720473.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jan;53(1):51-9 [10206072.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Acta Oncol. 1999;38(5):597-601 [10427948.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):937-42 [10509155.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):993-6 [10509165.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):2012-7 [15558072.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):188-94 [15687361.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2477-92 [15767642.001]
  • [Cites] Oncologist. 2005 Apr;10(4):242-9 [15821244.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1343-8 [15865089.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21 [16361558.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9304-11 [16361629.001]
  • [Cites] Clin Breast Cancer. 2006 Feb;6(6):511-7 [16595034.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 Jun 1;44(11):745-7 [16836921.001]
  • [Cites] Breast Cancer Res. 2006;8(3):R31 [16790076.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):786-90 [18258987.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):73-6 [18353206.001]
  • (PMID = 19845944.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2770573
  •  go-up   go-down


5. Garg AK, Oh JL, Oswald MJ, Huang E, Strom EA, Perkins GH, Woodward WA, Yu TK, Tereffe W, Meric-Bernstam F, Hahn K, Buchholz TA: Effect of postmastectomy radiotherapy in patients &lt;35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys; 2007 Dec 1;69(5):1478-83
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy.
  • The objective of this study was to assess the benefits of PMRT in patients <35 years old treated with doxorubicin-based neoadjuvant chemotherapy for Stage II-III breast cancer.
  • PATIENTS AND METHODS: We retrospectively analyzed 107 consecutive breast cancer patients <35 years old with Stage IIA-IIIC disease treated at our institution with doxorubicin-based neoadjuvant chemotherapy and mastectomy, with or without PMRT.
  • The treatment groups were compared in terms of LRC and overall survival.
  • CONCLUSION: Among breast cancer patients <35 years old at diagnosis, the use of PMRT after doxorubicin-based neoadjuvant chemotherapy and mastectomy led to a statistically greater rate of LRC and overall survival compared with patients without PMRT.
  • The benefit seen for PMRT in young patients provides valuable data to better tailor adjuvant, age-specific treatment decisions after mastectomy.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Mastectomy
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Doxorubicin / therapeutic use. Female. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855016.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / L30 CA123630; United States / NCI NIH HHS / CA / L30 CA123630-01; United States / NCI NIH HHS / CA / L30 CA123630-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS283623; NLM/ PMC4329785
  •  go-up   go-down


6. Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G: Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist; 2006 Jun;11(6):563-73
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
  • BACKGROUND: Based on phase II data in advanced breast cancer (BC), the fluorouracil, epirubicin, and vinorelbine (FEN) combination was assessed as perioperative chemotherapy, integrated in a multidisciplinary treatment for locally advanced BC.
  • PATIENTS AND METHODS: Patients with newly diagnosed inoperable (stage IIIB or inflammatory) BC.
  • Multimodality treatment protocol consisted of four preoperative courses of fluorouracil (600 mg/m(2) day 1), epirubicin (75 mg/m(2) day 1), and vinorelbine (25 mg/m(2) day1 and day 8), all i.v. every 21 days, followed by radical or conservative surgery according to clinical response and four postoperative identical chemotherapy courses aimed to eradicate micrometastatic disease.
  • Locoregional radiotherapy was offered to all patients after the completion of chemotherapy followed by hormonotherapy according to hormone receptor status.
  • RESULTS: Forty-eight women, one stage IIIA, 27 (56.2%) stage IIIB, two stage IIIC (4.1%), and 12 (25%) with inflammatory BC, aged 34-75 years (median, 52), were accrued.
  • Thirty-eight and 34 patients completed the planned pre- and postoperative chemotherapy, respectively.
  • Toxicity of both phases, mainly hematologic, was in general acceptable without treatment-related death.
  • All but three tumors were converted to operable, 31.3% with breast conservation.
  • After a median follow-up of 72 months, 62.5% and 16.7% of patients remain relapse free at 3 and 5 years, respectively, while 83% and 58.3% were alive 3 and 5 years, respectively, after the start of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Survival Rate

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794236.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; U3P01618RT / Fluorouracil; FEN protocol
  •  go-up   go-down


7. Shenkier T, Weir L, Levine M, Olivotto I, Whelan T, Reyno L, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ; 2004 Mar 16;170(6):983-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.
  • OBJECTIVE: To define the optimal treatment for women with stage III or locally advanced breast cancer (LABC).
  • RECOMMENDATIONS: The management of LABC requires a combined modality treatment approach involving surgery, radiotherapy and systemic therapy.
  • Systemic therapy: chemotherapy.
  • Patients with operable stage IIIA disease should be offered chemotherapy.
  • They should receive adjuvant chemotherapy following surgery, or primary chemotherapy followed by locoregional management.
  • Chemotherapy should contain an anthracycline.
  • Patients with stage IIIB or IIIC disease, including those with inflammatory breast cancer and those with isolated ipsilateral internal mammary or supraclavicular lymph-node involvement, should be treated with primary anthracycline-based chemotherapy.
  • Acceptable chemotherapy regimens are FAC, CAF, CEF or FEC.
  • Patients with stage IIIB or IIIC disease who respond to primary chemotherapy should be treated until the response plateaus or to a maximum of 6 cycles (minimum 4 cycles).
  • Patients with stage IIIB disease should then undergo definitive surgery and irradiation.
  • The locoregional management of patients with stage IIIC disease who respond to chemotherapy should be individualized.
  • In patients with stage IIIB or IIIC disease who achieve maximum response with fewer than 6 cycles, further adjuvant chemotherapy can be given following surgery and irradiation.
  • Patients whose tumours do not respond to primary chemotherapy can be treated with taxane chemotherapy or can proceed directly to irradiation followed by modified radical mastectomy, if feasible.
  • Systemic therapy: hormonal therapy.
  • Patients with stage IIIA disease should receive both modified radical mastectomy (MRM) and locoregional radiotherapy if feasible.
  • They may be managed with MRM followed by chemotherapy and locoregional radiotherapy, or chemotherapy first followed by MRM and locoregional radiotherapy.
  • Breast-conserving surgery is currently not a standard approach.
  • Patients with stage IIIB disease who respond to chemotherapy should receive surgery plus locoregional radiotherapy.
  • The locoregional management of patients with stage IIIC disease who respond to chemotherapy is unclear and should be individualized.
  • Patients whose disease remains inoperable following chemotherapy should receive locoregional radiotherapy with subsequent surgery, if feasible.
  • VALIDATION: The authors' original text was revised by members of the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
  • SPONSOR: The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer was convened by Health Canada.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Mastectomy. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3412-7 [10550135.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(2):151-6 [10674880.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1220-9 [10715291.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1558-69 [10735905.001]
  • [Cites] N Engl J Med. 2000 Apr 13;342(15):1069-76 [10760307.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):602-11 [11157009.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):628-33 [11157012.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1539-69 [11230499.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2131-9 [12090977.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3317-27 [12149306.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3628-36 [12202663.001]
  • [Cites] Clin Breast Cancer. 2002 Oct;3 Suppl 2:S69-74 [12435290.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):298-305 [12525522.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):843-50 [12610183.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):851-4 [12610184.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):976-83 [12637460.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4165-74 [14559892.001]
  • [Cites] Cancer. 1978 May;41(5):1649-57 [348293.001]
  • [Cites] Cancer Clin Trials. 1981 Fall;4(3):229-36 [7026073.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1284-90 [6337698.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1751-7 [4044337.001]
  • [Cites] Aust N Z J Surg. 1986 Jan;56(1):39-41 [3090987.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1583-7 [3759583.001]
  • [Cites] Breast Cancer Res Treat. 1987;9(1):39-44 [3593990.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):936-42 [3300953.001]
  • [Cites] J Clin Oncol. 1988 Feb;6(2):261-9 [3276824.001]
  • [Cites] Cancer. 1988 Dec 15;62(12):2507-16 [3056604.001]
  • [Cites] Chest. 1989 Feb;95(2 Suppl):2S-4S [2914516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Aug;17(2):257-61 [2666363.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1483-96 [2202791.001]
  • [Cites] Eur J Cancer. 1990;26(6):674-9 [2168190.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):319-23 [2061108.001]
  • [Cites] Eur J Cancer. 1991;27(8):973-7 [1832906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):949-60 [1639655.001]
  • [Cites] Cancer Invest. 1993;11(4):363-70 [8324641.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1253-9 [8080512.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):466-76 [8004622.001]
  • [Cites] Eur J Cancer. 1994;30A(5):645-52 [8080680.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):547-52 [7884414.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1152-9 [7537798.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1283-7 [7779724.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2886-94 [8523051.001]
  • [Cites] Eur J Surg Oncol. 1996 Feb;22(1):34-7 [8846863.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1885-94 [8656257.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):207-15 [8996144.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1061-6; discussion 1067-8 [9070481.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1138-49 [9070491.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):45-9 [9071898.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] N Engl J Med. 1997 Oct 2;337(14):949-55 [9395428.001]
  • [Cites] N Engl J Med. 1997 Oct 2;337(14):956-62 [9309100.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):93-100 [9440728.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2651-8 [9704715.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Ann Oncol. 1998 Nov;9(11):1179-84 [9862047.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):47-52 [10076721.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1641-8 [10335782.001]
  • [CommentIn] CMAJ. 2004 Aug 3;171(3):220-1; author reply 221-2 [15289405.001]
  • [CommentIn] CMAJ. 2004 Aug 3;171(3):219-20; author reply 221-2 [15289403.001]
  • [CommentIn] CMAJ. 2004 Aug 3;171(3):219; author reply 221-2 [15289404.001]
  • (PMID = 15023926.001).
  • [ISSN] 0820-3946
  • [Journal-full-title] CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
  • [ISO-abbreviation] CMAJ
  • [Language] eng
  • [Publication-type] Guideline; Journal Article; Practice Guideline; Review
  • [Publication-country] Canada
  • [Number-of-references] 73
  • [Other-IDs] NLM/ PMC359433
  •  go-up   go-down


8. Battelli N, Massacesi C, Braconi C, Pilone A, Manzione L, Dinota A, Cobelli S, Scanni A, Sturba F, Giacomini G, Morale D, Giorgi F, Tummarello D, Cascinu S: Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. Am J Clin Oncol; 2006 Aug;29(4):380-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
  • OBJECTIVE: The aim of this study was to evaluate the feasibility of a combination of epirubicin and paclitaxel followed by intravenous (iv) cyclophosphamide, methotrexate, and 5-fluorouracile (CMF) as adjuvant treatment of breast cancer patients with 10 or more metastatic axillary lymph nodes.
  • Sites of relapse were mainly bone, skin/soft tissues, liver, and lung.
  • CONCLUSIONS: The combination of paclitaxel at low dose and epirubicin followed by CMF is a feasible regimen, which seems to be effective in high-risk node positive breast cancer patients and requires further investigations.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Mastectomy. Methotrexate / administration & dosage. Middle Aged. Paclitaxel / administration & dosage. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891866.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down


9. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML: American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst; 2005 Aug 3;97(15):1137-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
  • BACKGROUND: Response to neoadjuvant chemotherapy is used as an intermediate endpoint for breast cancer relapse and survival.
  • Most breast cancer response classification systems use pathologic complete response, either alone or in conjunction with clinical assessments, to categorize response.
  • We examined the ability of the revised 2003 American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system, which considers both the number of involved axillary lymph nodes and the extent of tumor in the breast to predict patient survival after neoadjuvant chemotherapy for breast cancer.
  • METHODS: We assessed the pathologic stage of residual tumor in 132 patients with nonmetastatic breast cancer after they had undergone neoadjuvant chemotherapy and examined the association between AJCC TNM stage and subsequent distant disease-free survival and overall survival.
  • RESULTS: At a median follow-up of 5 years, pathologic stage in the surgical specimens after neoadjuvant chemotherapy using the revised AJCC system was strongly associated with both distant disease-free survival and overall survival.
  • A higher pathologic stage of residual tumor after neoadjuvant chemotherapy was associated with a statistically significant lower rate of distant disease-free survival (stage 0: 95%, stage I: 84%, stage II: 72%, and stage III: 47%; Ptrend < .001).
  • The 5-year distant disease-free survival for patients with residual stage IIIC tumors was only 18% (95% CI = 0% to 36%).
  • CONCLUSION: Classification of residual tumor in the breast and axillary surgical specimens after neoadjuvant chemotherapy using the revised AJCC TNM system is useful for predicting distant relapse and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / classification. Breast Neoplasms / drug therapy. Lymph Nodes / pathology. Neoadjuvant Therapy. Neoplasm Staging / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy / methods. Middle Aged. Neoplasm, Residual. Prognosis. Proportional Hazards Models. Survival Analysis. United States

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077072.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA58223; United States / NCRR NIH HHS / RR / M01RR00046
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


10. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Cancer Radiother; 2004 Jun;8(3):155-67
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
  • [Transliterated title] Cancer du sein localement évolué non inflammatoire traité par association de chimiothérapie et de radiothérapie à dose préopératoire: réactualisation des résultats d'une série de 120 patientes.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a study of locally advanced non inflammatory breast cancer after primary chemotherapy followed by external preoperative irradiation.
  • PATIENTS AND METHODS: Between 1982 and 1998, 120 patients (75 stage IIIA, 41 stage IIIB, and 4 stage IIIC according to AJCC staging system 2002) were consecutively treated by four courses of induction chemotherapy with anthracycline-containing combinations followed by preoperative irradiation (45 Gy to the breast and nodal areas) and a fifth course of chemotherapy.
  • After completion of local therapy, all patients received a sixth course of chemotherapy and a maintenance adjuvant chemotherapy regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumour larger than 3 cm in diameter or located behind the nipple or with bifocal tumour), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumour bed; 32 had residual mass <or=3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumour size (<6 vs. >or=6 cm in diameter, p =0.002).
  • After multivariate analysis, metastatic disease-free survival rates were significantly influenced by clinical stage (stage IIIA-B vs. IIIC, p =0.0003), N-stage (N0 vs. N1-2a, and 3c, p =0.017), initial tumour size (<6 vs. >or=6 cm in diameter, p =0.008), and tumour response after induction chemotherapy and preoperative irradiation (clinically complete response + partial response vs. non-response, p =0.0015).
  • In the non conservative breast treatment group, of the 32 patients with no change in clinical tumour size after induction chemotherapy, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • CONCLUSION: Despite the poor prognosis of patients with locally advanced non inflammatory breast cancer resistant to primary anthracycline-based regimen, aggressive locoregional management using preoperative irradiation and mastectomy with axillary dissection offers a possibility of long term survival with low local failure rate for patients without extensive nodal disease.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumour response following induction chemotherapy and breast-conserving treatment combining preoperative irradiation and large wide excision.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217583.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol; 2005 Jan 1;23(1):41-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
  • PURPOSE: To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome.
  • PATIENTS AND METHODS: The study included 1,034 patients with stage II and III breast cancer who participated in six clinical trials of PC at our institution between 1985 and 2002.
  • Pathologic complete response (pCR) was defined as no evidence of invasive disease in the breast and axillary lymph nodes.
  • Patients with ILC tended to be older (median age, 53 years v 47 years for patients with IDC) and have more hormone-receptor-positive tumors (92% v 62%; P < .001), lower nuclear grade (nuclear grade 3, 16% v 56%; P < .001), and higher stage at diagnosis (10% v 0% with stage IIIB or IIIC disease; P < .001).
  • At a median follow-up time of 70 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival (P = .001).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Axilla. Bridged Compounds / therapeutic use. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Disease-Free Survival. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / mortality. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6796; author reply 6796-7 [16170189.001]
  • [ErratumIn] J Clin Oncol. 2013 Aug 10;31(23):2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A]
  • (PMID = 15625359.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


12. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):1062-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a prospective study of locally advanced noninflammatory breast cancer (LABC) after primary chemotherapy (CT) followed by external preoperative irradiation (RT).
  • METHODS AND MATERIALS: Between 1982 and 1998, 120 patients (75 Stage IIIA, 41 Stage IIIB, and 4 Stage IIIC according to AJCC staging system 2002) were treated by four courses of induction CT with anthracycline-containing combinations followed by preoperative RT (45 Gy to the breast and nodal areas) and a fifth course of CT.
  • Three different locoregional approaches were proposed depending on tumor characteristics and tumor response.
  • After completion of local therapy, all patients received a sixth course of CT and a maintenance adjuvant CT regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumor larger than 3 cm in diameter or located behind the nipple or with bifocal tumor), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumor bed; 32 had residual mass < or =3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.002).
  • After multivariate analysis, metastatic disease-free survival rates were significantly influenced by clinical stage (Stage IIIA-B vs. IIIC, p = 0.0003), N-stage (N0 vs. N1-2a, and 3c, p = 0.017), initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.008), and tumor response after induction CT and preoperative RT (clinically complete response + partial response vs. nonresponder, p = 0.0015).
  • In the nonconservative breast treatment group, of the 32 patients with no change in clinical tumor size after induction CT, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumor response after induction CT and breast-conserving treatment combining preoperative RT and large wide excision.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cobalt Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234040.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


13. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN: Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol; 2005 Oct 1;23(28):7098-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
  • PURPOSE: To identify clinicopathological factors predictive of distant metastasis in patients who had a pathologic complete response (pCR) after neoadjuvant chemotherapy (NC).
  • Clinical stage at diagnosis was I (2%), II (36%), IIIA (27%), IIIB (23%), and IIIC (12%).
  • Eleven percent of all patients were inflammatory breast cancers (IBC).
  • Ninety-five percent received anthracycline-based chemotherapy; 42% also received taxane-based therapy.
  • Multivariate Cox regression analysis using combined stage revealed that clinical stages IIIB, IIIC, and IBC (hazard ratio [HR], 4.24; 95% CI, 1.96 to 9.18; P < .0001), identification of < or = 10 lymph nodes (HR, 2.94; 95% CI, 1.40 to 6.15; P = .004), and premenopausal status (HR, 3.08; 95% CI, 1.25 to 7.59; P = .015) predicted for distant metastasis.
  • CONCLUSION: A small percentage of breast cancer patients with pCR experience recurrence.
  • Our data suggest that premenopausal patients with advanced local disease and suboptimal axillary node evaluation may be candidates for clinical trials to determine whether more aggressive or investigational adjuvant therapy will be of benefit.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Metastasis
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Premenopause. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192593.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Costa SD, Loibl S, Kaufmann M, Zahm DM, Hilfrich J, Huober J, Eidtmann H, du Bois A, Blohmer JU, Ataseven B, Weiss E, Tesch H, Gerber B, Baumann KH, Thomssen C, Breitbach GP, Ibishi S, Jackisch C, Mehta K, von Minckwitz G: Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data. J Clin Oncol; 2010 Jan 1;28(1):83-91
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data.
  • PURPOSE Neoadjuvant chemotherapy followed by mastectomy is the treatment of choice in patients with inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC), but it is considered less effective in these diseases than in operable breast cancer (OBC).
  • We report a prospective comparison of the GeparTrio trial of patients with IBC (cT4 days) or LABC (cT4a-c or cN3; stage IIIB or IIIC) and patients with OBC (cT2-3).
  • PATIENTS AND METHODS Participants were stratified by stage and were randomly assigned to six or eight cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) or to two cycles of TAC followed by four cycles of vinorelbine/capecitabine.
  • We present results of a secondary aim of the study, which was to compare pathologic complete response (pCR; ie, no remaining invasive/noninvasive tumor in breast and lymph nodes) in different stage groups.
  • At baseline, parameters were as follows for the three types of cancer, respectively: median tumor sizes: 8.0 cm, 7.0 cm, and 4.0 cm (P < .001); multiple lesions: 31.2%, 27.3%, and 19.6% (P < .001); nodal involvement: 86.6%, 71.2%, and 51.6% (P < .001); grade 3: 44.4%, 30.4%, and 39.9% (P = .178); lobular-invasive type: 7.5%, 17.5%, and 13.3% (P = .673); negative hormone receptor status: 38.0%, 20.0%, and 36.4% (P = .008); and positive human growth factor receptor 2 status: 45.1%, 38.9%, and 35.7% (P = .158).
  • Response rates for IBC, LABC, and OBC, respectively, were 8.6%, 11.3%, and 17.7% for pCR (P = .002); 71.0%, 69.6%, and 83.4% for overall response by physical or sonographic examination (P < .001); and 12.9%, 33.0%, and 69.9% for breast conservation (P < .001).
  • However, tumor stage itself was not an independent predictor for pCR in multivariable analysis (odds ratio, 1.51; 95% CI, 0.88 to 2.59; P = .13).
  • CONCLUSION No evidence of a difference in response to neoadjuvant chemotherapy was found by tumor stage when analysis was adjusted for baseline characteristics.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Prospective Studies

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19901111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Smith JW, Buyse M, Rastogi P, Geyer C Jr, Jacobs S, Patocskai E, Wolmark N: Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group. J Clin Oncol; 2009 May 20;27(15_suppl):580

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group.
  • : 580 Background: A previous phase II study evaluating the combination of trastuzumab (tras) and bevacizumab (bev) as first-line therapy in HER2 + MBC showed a response rate of 54%.
  • Targeted therapy: Cohort A (neoadjuvant), bev 15 mg/kg IV with Cycle 4 of EC, continued with the first 3 cycles of T.
  • Standard weekly tras with 4 cycles of T.
  • Postop, bev 15 mg/kg IV and tras 6 mg/kg IV q3wks to complete 1 yr of targeted therapy.
  • Cohort B (adjuvant), bev 15 mg/kg q3wks for 4 cycles and weekly tras with T.
  • After chemotherapy, bev and tras q3wks to complete 1 yr of therapy.
  • Primary endpoints were the rate of cardiac events in both cohorts and pCR rate in breast/axillary lymph nodes in Cohort A.
  • In Cohort A, 28 (53%) patients (pts) were stage IIIA, 20 (38%) stage IIIB, and 5 (9%) stage IIIC.
  • Toxicity information on the first 73 pts in both cohorts showed that grade 2 LVEF dysfunction has developed in 5 pts and grade 3 LVEF dysfunction in 2, 1 with NYHA Class II and 1 with Class III symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960693.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Caudle AS, Gonzalez-Angulo AM, Kelly HK, Liu P, Pusztai L, Symmans WF, Kuerer HM, Mittendorf EA, Hortobagyi GN, Meric-Bernstam F: Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):603

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
  • : 603 Background: While most patients with breast cancer receiving neoadjuvant chemotherapy (NCT) have some tumor response, a small proportion progress during therapy.
  • The goal of this study was to identify predictors of tumor progression during NCT with the ultimate aim of identifying the subset of patients who may benefit from a first-line surgical approach.
  • METHODS: Patients with stage I-III breast cancer treated at a single comprehensive cancer center with NCT between 1994 and 2007 were included.
  • Chemotherapy consisted of anthracycline and/or taxane-based regimens.
  • Clinical factors that correlate with PD in univariate analysis include presenting T (T3 vs T1, p = 0.002) and AJCC stage (stage IIIb/IIIc vs I/II/III, p = 0.02).
  • Predictive histopathological features were high tumor grade (p = 0.005), high Ki-67 (p = 0.002), and negative ER and PR status (p < 0.0001 and p = 0.0006).
  • In the post-NCT surgical specimens, patients with PD were more likely to have higher T stage (p < 0.0001), lymph node metastasis (p = 0.01), and lymphovascular invasion (p = 0.02).
  • CONCLUSIONS: Pre-treatment characteristics predictive of disease progression on NCT include advanced tumors, high tumor grade, high Ki-67, and negative ER or PR status.
  • Since high grade and negative ER/PR status have also been associated with a complete pathologic response to NCT, there is a clear need for more specific molecular predictors of response and progression in order to select appropriate treatment in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961464.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Rastogi P, Buyse M, Swain S, Jacobs S, Robidoux A, Liepman M, Dy P, Geyer C Jr, Wolmark N: Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group. J Clin Oncol; 2009 May 20;27(15_suppl):584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group.
  • : 584 Background: Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer.
  • The purpose of this trial was to determine the activity and safety profile of bevacizumab with chemotherapy in women with LABC.
  • Bevacizumab 15 mg/kg IV was given concurrently with chemotherapy every 21 days for a total of 6 preoperative doses.
  • Primary endpoint was pathologic complete response rate (pCR) in the breast.
  • 30 patients had stage IIIA (67%), 12 stage IIIB (27%), and 3 stage IIIC (7%) disease.
  • Of these, 10 (22%) had inflammatory breast cancer.
  • A pCR in the breast was documented in 4/44 (9%) patients, which included negative axillary nodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960695.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Vicente A, García-Martínez E, Gonzalez-Billalabeitia E, Zafra M, Castilla-Llorente C, García-García T, Macías J, García-Garre E, Vicente V, Ayala de la Peña F: Prognostic value of decrease on blood lymphocytes in breast cancer patients undergoing primary chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of decrease on blood lymphocytes in breast cancer patients undergoing primary chemotherapy.
  • : e11537 Background: There is evidence about chemotherapy creating a better tumor control by inmune system.
  • Neoadjuvant treatment is an excellent situation to study tumor behaviour.
  • The aim of this study is to determine whether decreases on blood lymphocytes (BL) absolute number have a prognostic significance on women with breast cancer receiving primary chemotherapy (PC).
  • METHODS: A retrospective analysis was performed of 105 breast cancer patients who underwent PC.
  • RESULTS: Of 105 patients with breast cancer 16,2% were clinical stage IIA, 19% IIB, 30,5% IIIA, 14,3% IIIB, 15,2% IIIC.
  • The complete pathologic response (pCR) rate was 14,9% in primary tumor, and 37,9% in axillary nodes.
  • CONCLUSIONS: A decrease on blood lymphocyte number in women with breast cancer undergoing primary chemotherapy is correlated with worse DFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964682.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Buchholz TA, Woodward WA, Tucker SL, Strom EA, Hunt KK, Buzdar AU, Perkins GH, Schechter NR, Hortobagyi GN: Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining the competing risk of local-regional and distant recurrence in 1,256 patients treated with mastectomy and doxorubicin-based adjuvant chemotherapy.
  • : 555 Background: It has been suggested that patients with 1-3 positive lymph nodes (+LN) (Stage II) are more likely to achieve a survival benefit from postmastectomy radiation (PMRT) than those with 4-9 +LN (Stage IIIA), because patients with Stage II disease have a lowerer competing risk of distant metastases (DM).
  • To evaluate this, we compared the proportional risks of local-regional recurrence (LRR) and DM according to stage of disease and whether treatment included PMRT.
  • METHODS: We retrospectively studied the records of 1256 patients who met the following criteria: treatment with mastectomy and doxorubicin-based adjuvant chemotherapy; treatment on an institutional prospective clinical trial; sufficient information available to retrospectively restage the extent of disease according to 2003 AJCC pathological staging guidelines; and pathological stage IIA-IIIC disease.
  • RESULTS: After a median follow-up of 10.4 years, the crude rates of developing a LRR or DM according to stage were: IIA-19%, IIB-39%, IIIA-48%, IIIB/C-64%.
  • The table shows the percentage of total events that were isolated LRR within each stage according to the use of radiation.
  • The greatest percentage of of total events that were isolated LRR occurred in patients with stage IIIA disease and accordingly, PMRT had the greatest reduction in the percentage of total events that were isolated LRR in these patients.
  • CONCLUSIONS: Postmastectomy radiation reduces the percentage of events that are LRR across all subcategories of stage II and III breast cancer.
  • When considered in light of the competing risk of DM, radiation would be predicted to have the biggest survival benefit for patients with 4-9 +LN (stage IIIA disease).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Franco EE, Silva JA, Perez M, Silva M, Villalobos R, Labastida S, Olivares G, Castruita AL: Docetaxel as adjuvant therapy on patients with locally advanced breast cancer (LABC), after neoadjuvant chemotherapy with anthracyclines followed by radical surgery +/- radiotherapy. J Clin Oncol; 2004 Jul 15;22(14_suppl):743

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel as adjuvant therapy on patients with locally advanced breast cancer (LABC), after neoadjuvant chemotherapy with anthracyclines followed by radical surgery +/- radiotherapy.
  • : 743 Background:The aim was to determine the benefit in Disease Free Survival (DFS) and Overall Survival (OS) of the docetaxel as adjuvant therapy LABC after multimodal therapy.
  • METHODS: 761 patients with diagnosis of breast cancer were revised.
  • 130 patients met criteria with stages II-B (T3N0M0), III-A, III-B, III-C that received treatment from Jan 1999 to March 2003.
  • Combined modality consisted on a first phase with neoadjuvant chemotherapy (NCT) with anthracyclines, followed by Radical Mastectomy (RM) +/- Radiotherapy and Docetaxel for 4 cycles as adjuvant therapy.
  • RESULTS: 51.5% had Stage III-A and 40% III-B,8.5% other (IIb, IIIC).
  • There were not statistically significant differences in the analysis according to the different clinical stages, pathological tumor size, histology, menopausical state, HER-2/neu expression neither vasculo/lymphatic permeation.
  • CONCLUSIONS: Results suggest that adjuvant chemotherapy with 4 cycles of docetaxel as part of the multimodal therapy in LABC could benefit this group of patients, however it is necessary a longer follow-up in order to know the real impact in survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013630.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bautista Aragón YL, Silva J, Gonzalez Avila G, Gutierrez A, Pluma-Jiménez M: Dose-dense epirubicin with paclitaxel as preoperative treatment in locally advanced breast cancer: Phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e11633

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-dense epirubicin with paclitaxel as preoperative treatment in locally advanced breast cancer: Phase II trial.
  • : e11633 Background: Treatment of locally advanced breast cancer (LABC) with anthracycline-based regimens have pathological complete response (pCR) of 10-15%, and with anthracyclin-taxane therapy have pCR 18-30%.
  • This phase II study investigated women with untreated locally advanced breast cancer assigned to receive epirrubicina 25 mg/m2 and paclitaxel 70 mg/m2 for twelve weeks.
  • The distribution by TNM was IIB (15%), IIIA (52%), IIIB (24%) y IIIC (9%) and tumor type was lobular (24%) and ductal (76%).
  • The mean tumor size was 8 cm (5 -14 cm).
  • Ninety percent completed twelve cycles of chemotherapy with a two hundred forty five cycles administered.
  • In six patients had dose reduction by 10-20% in subsequent doses and one patient withdrawn from de study because of chemotherapy related toxicity.
  • Subset analysis of the effect of Independent predictors included receptor status, Her2 neu, tumor size, and histology was no statistically significant (p.68).
  • Treatment was generally well tolerated.
  • However we have low percent of cPR, maybe we have a high percent of patients with stage IIIA and IIIB with large diameter of tumor size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Zamagni C, De Iaco P, Rosati M, Cacciari N, Rosati F, Rubino D, Martoni AA: Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):5513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer.
  • : 5513 Background: The role and the duration of NACT in ovarian cancer are debated.
  • The rate of pCR correlates with a better survival in other tumors, such as breast cancer, and its rate is higher after 6-8 courses of NACT.
  • METHODS: Eligible pts had stage IIIC-IV EOC unsuitable for optimal upfront surgery and were treated with 6 cycles of carboplatin AUC 5 and paclitaxel 175 mg/sm, every 3 weeks before surgery.
  • 1) the pts with absence of cancer cells in surgical specimens, and 2) the pts with no macroscopic residual after surgery and with only small clusters or individual cancer cells in surgical specimens.
  • All the other cases were considered as pathological nonresponders, even if a relevant shrinkage of tumor burden and an optimal surgical debulking were obtained.
  • RESULTS: 35 stage IIIC/IV pts were enrolled; 33 (94%) completed 6 courses of NACT.
  • Overall, in 20 (57%) pts the goal of no residual tumor after surgery was achieved.
  • As expected, pts with tumor residual after surgery less than 1 cm survived significantly longer than patients with a greater residual (p .0005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Blakely L, Somer B, Keaton M, Hermann R, Schnell F, Cobb P, Johns A, Walker M, Schwartzberg L: Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer.
  • : 595 Background: Neoadjuvant (Neo) chemotherapy (CT) with trastuzumab (H) improves pathologic complete response (pCR) rate for HER2+ breast cancer.
  • Dose-dense regimens improve outcome in the adjuvant setting but have not been fully evaluated as preoperative therapy.
  • METHODS: Patients (pts) with biopsy proven, clinical stage IIA-IIIC, noninflammatory breast cancer were eligible.
  • EF was measured prior to CT, after EC, after TH and at 6, 12 and 24 months after surgery.
  • Additional adjuvant H to complete 1 year of therapy by conventional schedule was recommended after surgery.
  • The primary endpoint was pCR for invasive cancer in breast and lymph nodes.
  • RESULTS: 30 pts were enrolled at 5 centers: median age was 50.1 (range, 31-72); ethnicity African-American 14, Caucasian 14, other 2; clinical stage IIA, 14, IIB, 4, IIIA, 7, IIIB/C, 5; ER+ 18, PR+ 14; grade 3, 21 and grade 2, 8.
  • Twenty eight pts were evaluable for pathologic response- 2 withdrew before completing treatment, 1 for toxicity.
  • Dose delivery on schedule was >95% for all drugs.
  • Mean EF was 63.1 (range, 51-81) before treatment, 62.4 (49-75) after EC and 58.3 (35-74) after TH.
  • Two pts had EF <50% during Neo, one with clinical CHF and 1 additional pt developed CHF during adjuvant single agent H.
  • CONCLUSIONS: Sequential Neo dose-dense Q 14 day EC followed by Q 14 day TH yields a high pCR rate in HER2+ breast cancer with acceptable toxicity profile and no new safety signals noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960705.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Mates M, Hopman W, Madarnas Y: Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario. J Clin Oncol; 2009 May 20;27(15_suppl):e11614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of care and outcomes of locally advanced breast cancer at the Cancer Centre of Southeastern Ontario.
  • : e11614 Background: Preoperative chemotherapy (PCT) is the standard of care for locally advanced breast cancer (LABC).
  • METHODS: We reviewed electronic and paper records for M<sub>0</sub> pts receiving PCT for LABC between 1995-2007 at our institution, collecting demographic, disease and treatment-related, and outcome variables.
  • Stage distribution: 10% IIB, 11% IIIA, 77% IIIB and 2% IIIC, of which 45% had inflammatory breast cancer (IBC).
  • At biopsy 90% were invasive ductal carcinoma, 36% were ER and PR(-) and 25% were her2(+).
  • Median time from surgical consultation to PCT was 22d (6-126).
  • PCT was anthracycline-based alone in 85% of pts, 8% received a taxane, 3% also received preop endocrine therapy (ET), no pts received trastuzumab (T) preop.
  • Local therapy: mastectomy (M) in 82% of pts and partial M in 11%.
  • Axillary surgery was done in only 92% of pts (axillary node dissection 90%, sentinel node biopsy 1pt) and 7% had no definitive breast or axillary surgery due to local progression (3) or refusal (1).
  • Postop systemic therapy: CT in 5% of pts, ET in 65% and T in 10% of pts.
  • At definitive surgery 10% of pts had no residual disease in breast or axilla and 3 pts had only DCIS present, for a pathologic (p)CR rate of 15% using MDACC criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961135.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Gonzalez-Angulo AM, Kau SW, Broglio K, Buzdar AU, Theriault RL, Valero V, Sneige N, Frye D, Hortobagyi GN, Cristofanilli M: Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. J Clin Oncol; 2004 Jul 15;22(14_suppl):663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features.
  • : 663 Background: classic ILC represents 5-10% of all primary breast cancers (BC).
  • Its histological growth pattern makes early diagnosis, staging and surgical approach difficult.
  • Induction chemotherapy (IC) is used to downstage tumors and facilitate breast conservative surgery.
  • METHODS: 1034 patients (pts) with stage II and III BC participated in six clinical trials using IC at M.D.
  • Anderson Cancer Center between 1985 and 2002.
  • All pts received anthracycline-based chemotherapy and 246 pts (23.8%) also received a taxane. pCR was defined as no evidence of invasive BC in the breast and axillary lymph nodes.
  • The stratified log-rank test was used to assess differences between OS and RFS among the groups and after adjustments for hormone receptor (HR) status, stage, and pCR.
  • The lobular group tended to be older (med, 53 vs. 47 yrs), have more HR positive tumors, (92% vs. 62%) lower nuclear grade (16% vs. 56% grade 3), and higher stage at diagnosis (10% vs. 0% were IIIB and IIIC).
  • These differences persisted after adjustment for HR status (p=0.02 and 0.03) and stage (both p=0.04).
  • CONCLUSION: ILC is a distinct histological type of breast cancer characterized by better outcome when compared to IDC in spite of the low pCR rate after IC.
  • The role of primary hormonal therapy should be assessed in ILC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM: Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res; 2009 Apr 15;15(8):2942-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
  • PURPOSE: Tipifarnib is a farnesyl transferase (FTase) inhibitor that has activity in metastatic breast cancer and enhances the efficacy of cytotoxic agents in preclinical models.
  • We evaluated the biological effects of tipifarnib in primary breast cancers in vivo, whether adding tipifarnib to preoperative chemotherapy increased the pathologic complete response rate (pCR) at surgery, and determined whether biomarkers predictive of pCR could be identified.
  • EXPERIMENTAL DESIGN: Forty-four patients with stage IIB-IIIC breast cancer received up to four cycles of neoadjuvant doxorubicin-cyclophosphamide (AC) every 2 weeks plus tipifarnib and filgrastim followed by surgery.
  • Enzymatic assays measuring FTase activity and Western blotting for phospho (p)-signal transducer and activator of transcription 3 (STAT3), phospho-extracellular signal-regulated kinase, p-AKT, and p27 were done in 11 patients who agreed to optional tissue biopsies before therapy and 2 hours after the final dose of tipifarnib during the first cycle, and predictive biomarkers were evaluated by immunohistochemistry in 33 patients.
  • The trial was powered to detect an improvement in breast pCR rate of 10% or less expected for AC alone to 25% for AC-tipifarnib (alpha = 0.05, beta = 0.10).
  • RESULTS: Eleven patients had a breast pCR (25%; 95% confidence interval, 13-40%).
  • Low tumor Ki-67 expression (below the median of 60%) at baseline was significantly associated with resistance to therapy (P = 0.01).
  • CONCLUSION: Tipifarnib inhibits FTase activity in human breast tumors in vivo, is associated with down-regulation of p-STAT3, and enhances the breast pCR rate, thus meriting further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Breast Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Farnesyltranstransferase / antagonists & inhibitors. Quinolones / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Middle Aged. Neoadjuvant Therapy. STAT3 Transcription Factor / antagonists & inhibitors. STAT3 Transcription Factor / metabolism. rho GTP-Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8922-9 [14695209.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2492-9 [12829668.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Dec;4(12):1428-35 [14763128.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4776-81 [3524819.001]
  • [Cites] Lab Invest. 1986 Dec;55(6):603-15 [2431221.001]
  • [Cites] Cancer Res. 1989 Jan 15;49(2):357-60 [2642738.001]
  • [Cites] J Biol Chem. 1993 Jul 25;268(21):15347-50 [8101839.001]
  • [Cites] Nat Med. 1995 Aug;1(8):792-7 [7585182.001]
  • [Cites] EMBO J. 1996 May 1;15(9):2174-83 [8641283.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1111-6 [9607567.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20243-51 [9685373.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3883-93 [15867388.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] Mol Cancer Ther. 2002 Jun;1(8):575-83 [12479217.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):185-91 [12838322.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4165-74 [14559892.001]
  • [Cites] Chemotherapy. 2003 Dec;49(6):303-8 [14671431.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3676-85 [15738535.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5983-92 [16087943.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1272-86 [16145048.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7265-77 [16145055.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8331-9 [16293864.001]
  • [Cites] N Engl J Med. 2006 Feb 23;354(8):809-20 [16495393.001]
  • [Cites] JAMA. 2006 Apr 12;295(14):1658-67 [16609087.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3013-8 [16769985.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4485-90 [16899593.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4414-22 [17785706.001]
  • [Cites] Cancer Lett. 2007 Dec 18;258(2):181-8 [17920763.001]
  • [Cites] ACS Chem Biol. 2007 Dec 21;2(12):799-809 [18154267.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):112-26 [10656439.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Genes Cells. 2000 Aug;5(8):593-601 [10947845.001]
  • [Cites] Exp Cell Res. 2001 Jan 1;262(1):17-27 [11120601.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):153-208 [11152757.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16161-7 [11154688.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2898-907 [11555608.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3544-50 [11705875.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):579-84 [11839578.001]
  • [Cites] Cell Death Differ. 2002 Jul;9(7):702-9 [12058275.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1664-7 [12200678.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):407-14 [14719076.001]
  • (PMID = 19351752.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098473-05; United States / NCI NIH HHS / CA / R01 CA098473-04; United States / NCI NIH HHS / CA / P30 CA013330-369020; United States / NCI NIH HHS / CA / N01CM62204; United States / NCI NIH HHS / CA / R01 CA098473-01; United States / NCI NIH HHS / CA / R01 CA098473-04S1; United States / NCI NIH HHS / CM / N01 CM062204; United States / NCI NIH HHS / CM / N01-CM-62204; United States / NCI NIH HHS / CA / R01 CA098473-02; United States / NCI NIH HHS / CA / R01 CA098473-05S1; United States / NCI NIH HHS / CA / R01 CA098473; United States / NCI NIH HHS / CA / R01CA98473; United States / NCI NIH HHS / CA / R01 CA098473-03S1; United States / NCI NIH HHS / CA / R01 CA098473-03; United States / NCI NIH HHS / CA / P30 CA013330; United States / NCI NIH HHS / CA / R01 CA098473-02S1; United States / NCI NIH HHS / CA / P30 CA013330-359020
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Quinolones; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.5.1.29 / Farnesyltranstransferase; EC 3.6.5.2 / rho GTP-Binding Proteins; MAT637500A / tipifarnib
  • [Other-IDs] NLM/ NIHMS105425; NLM/ PMC2785076
  •  go-up   go-down


27. Raspollini MR, Amunni G, Villanucci A, Castiglione F, Rossi Degl'Innocenti D, Baroni G, Paglierani M, Taddei GL: HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):181-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER-2/neu and bcl-2 in ovarian carcinoma: clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival.
  • The HER-2 oncogene, which is located on chromosome 17 and encodes for a tyrosine-kinase growth factor receptor, is amplified and HER-2/neu is overexpressed in 25% to 30% of breast carcinomas.
  • The authors analyzed the bcl-2 expression and the bcl-2 gene and HER-2/neu overexpression and amplification in FIGO stage IIIC, serous, G3, ovarian carcinomas obtained from living patients who had no evident disease 5 years after primary treatment compared with ovarian carcinomas obtained from patients, matched for stage, grade of differentiation, and treatment, who had died of progression of disease no later than 2 years after primary treatment. bcl-2 overexpression was statistically correlated with progression of disease during first-line chemotherapy (P=0.021).
  • The HER-2/neu status was found not to correlate with progression of disease during first-line chemotherapy.
  • Both bcl-2 and HER-2/neu expression were not statistically associated with the clinical outcome of ovarian cancer patients.
  • The knowledge of additional prognostic or even predictive factors, such as bcl-2 expression, in patients with advanced ovarian carcinoma before the primary chemotherapeutic treatment may help in the management of patients who require a more tailored treatment.
  • In addition, the gene amplification of the HER-2/neu suggests that HER-2 is a potential target for treatment in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785787.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


28. Rizzo M, Lund MJ, Mosunjac M, Bumpers H, Holmes L, O'Regan R, Brawley OW, Gabram S: Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer. Cancer; 2009 Jul 1;115(13):3009-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer.
  • BACKGROUND: Stage III breast cancers account for about 6% to 7% of all invasive breast cancers diagnosed annually in the United States.
  • In African American (AA) women, the incidence of stage III breast cancers is almost double that in Caucasian women.
  • The aim of this study was to correlate age, receptor status, nuclear grade, and differences in treatment modalities for stage III breast cancer in an inner-city hospital serving a large AA population.
  • METHODS: A retrospective review was performed for all stage III primary breast cancers diagnosed and or treated from 2000 to 2006.
  • RESULTS: : Of 840 primary invasive breast cancers, the authors identified 107 as stage III, 40.2% IIIA, 32.7% IIIB, 16.8% T4D, and 10.3% IIIC.
  • Stage IIIC patients were younger (P < .05).
  • TNT were more likely among the inflammatory breast cancers (50.0%) compared with the other 3 groups (P < .05).
  • Twenty-two patients (20.5%) refused chemotherapy, and 24 of the 91 patients (26.3%) who should have received chest wall radiation refused.
  • There was no difference in race, marital status, religion, or age in the patients that refused chemotherapy or radiation therapy versus the majority of patients in this series who received standard care.
  • CONCLUSIONS: Stage III breast cancers in AA women have distinct clinical characteristics.
  • A high number of these patients refused chemotherapy and radiation therapy.
  • Reasons for refusal need to be better defined so strategies can be implemented to improve compliance for these advanced stage patients.
  • [MeSH-major] African Americans. Breast Neoplasms / ethnology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Receptors, Estrogen / metabolism. Retrospective Studies. Treatment Refusal / ethnology. Treatment Refusal / statistics & numerical data

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466698.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  •  go-up   go-down


29. Moriya T, Fukatsu K, Ueda S, Iwaya K, Osaki A, Yamamoto J: [A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel]. Gan To Kagaku Ryoho; 2010 May;37(5):907-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel].
  • We report a case of giant advanced breast cancer with skin ulceration and bleeding (T4cN3M0, Stage IIIC) in which a significant QOL improvement was achieved with epirubicin and cyclophosphamide (EC) followed by weekly paclitaxel.
  • A 63- year-old postmenopausal woman presented in May 2008 with a giant ulcerated right breast tumor and extensive erythema of the involved skin.
  • She had discovered the tumor the previous year, but had not sought medical advice or treatment.
  • A core needle biopsy of the breast mass led to a diagnosis of an invasive ductal carcinoma negative for estrogen receptor, progester-one receptor, and HER2/neu protein expression.
  • Upon completion of this chemotherapy, the breast tumor and skin erythema had nearly disappeared.
  • Pathological examination showed only focal residual tumor cells and complete disappearance of cancer cells in the lymph nodes (Grade 2).
  • EC followed by weekly paclitaxel therapy was effective for the locally advanced ulcerative breast tumor, and significantly improved QOL in this patient with Stage III C advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Paclitaxel / therapeutic use
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Quality of Life. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495326.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Sakurai K, Fujisaki S, Matsuo S, Ogura M, Enomoto K, Kitajima A, Tani M, Amano S, Shiono M: [A case of advanced breast cancer with skin ulceration successfully treated with paclitaxel and toremifene therapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2484-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast cancer with skin ulceration successfully treated with paclitaxel and toremifene therapy].
  • We report a case of advanced breast cancer with skin ulceration and bleeding (T4bN3bM0, Stage IIIC) achieving a significant improvement of QOL by paclitaxel (PTX) and toremifene (TOR) therapy.
  • The patient was a 31-year-old woman who had ulcerative breast lump with skin ulcer.
  • A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma positive for estrogen receptor and progesterone receptor, and negative for HER2/neu protein expression.
  • The bleeding from the tumor disappeared after CEF chemotherapy.
  • The response for breast tumor after PTX and TOR therapy was evaluated as partial response, and the infraclavicular, subpectoral, and interpectoral lymph nodes metastasis disappeared.
  • PTX and TOR therapy were effective for advanced breast tumor, and can improve patient QOL and the clinical outcomes in Stage IIIC advanced breast cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Hemorrhage / complications. Hemorrhage / etiology. Paclitaxel / administration & dosage. Skin Ulcer / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037463.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Organic Chemicals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / tremifene; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


31. Sakurai K, Enomoto K, Tani M, Kitajima A, Amano S, Shiono M: [A case of advanced breast cancer successfully treated with paclitaxel and toremifene therapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2219-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast cancer successfully treated with paclitaxel and toremifene therapy].
  • We report a case of advanced breast cancer with skin ulceration and bleeding (T4bN3bM0: Stage IIIC) achieving a significant improvement of QOL by toremifene and paclitaxel therapy.
  • The patient was a 38-year-old woman with slight anemia who had ulcerative breast lump with skin ulcer.
  • A core needle biopsy for breast tumor led to a diagnosis of an invasive ductal carcinoma positive for estrogen receptor and progesteron receptor, and negative for HER2/neu protein expression.
  • The anemia and the bleeding from the tumor disappeared after FEC chemotherapy.
  • The response for breast tumor after paclitaxel and toremifene therapy was evaluated as partial response, and the infraclavicular, subpectoral, and interpectoral lymph nodes metastasis disappeared.
  • Paclitaxel and Toremifene therapy was effective for advanced breast tumor, and can improve a patient QOL and the clinical outcomes in Stage IIIC advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Paclitaxel / therapeutic use. Toremifene / therapeutic use
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106576.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 7NFE54O27T / Toremifene; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Franceschini G, Terribile D, Fabbri C, Magno S, D'Alba P, Chiesa F, Di Leone A, Masetti R: Management of locally advanced breast cancer. Mini-review. Minerva Chir; 2007 Aug;62(4):249-55
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of locally advanced breast cancer. Mini-review.
  • The term locally advanced breast cancer (LABC) encompasses a heterogeneous group of breast neoplasms; in the last revision of the American Joint Committee on Cancer (AJCC) staging system, all of stage III disease is considered locally advanced.
  • LABC constitutes up to 20% of breast cancer in medically underserved populations in the United States and up to 75% of breast cancers in developing countries.
  • The prognosis depends on tumor size, extent of lymph node involvement, and the presence or absence of an inflammatory component.
  • However, a multidisciplinary approach is always recommended combining surgery, radiotherapy and systemic therapy (chemotherapy and/or hormone therapy).
  • In this paper, we discuss the possible options in the management of operable (stage IIIA) and inoperable (stage IIIB-IIIC) LABC.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Decision Trees. Female. Humans. Mastectomy / methods. Neoadjuvant Therapy / methods. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641585.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 34
  •  go-up   go-down


33. Fan Y, Xu B, Liao Y, Yao S, Sun Y: A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients. Breast; 2010 Oct;19(5):365-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients.
  • Clinically, ipsilateral supraclavicular lymph node metastasis (ISLM) in breast cancer can be classified into 2 manifestations: metachronous and synchronous.
  • Synchronous ISLM (T1-4, N3, M0) is stage IIIc.
  • Metachronous ISLM is isolated supraclavicular lymph node relapse after curative treatment.
  • We retrospectively reviewed 2486 breast cancer patients.
  • Axillary lymph node metastasis status (P = 0.009) and chemotherapy after occurrence of ISLM (P = 0.016) were independent prognostic predictors for metachronous ISLM whilst primary tumor size (P = 0.016) and radiotherapy after diagnosis of ISLM (P = 0.022) were independent prognostic factors for synchronous ISLM.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Carcinoma, Lobular / pathology. Lymphatic Metastasis. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20399657.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Kayikçioğlu F, Boran N, Ayhan A, Güler N: Inflammatory breast metastases of ovarian cancer: a case report. Gynecol Oncol; 2001 Dec;83(3):613-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory breast metastases of ovarian cancer: a case report.
  • BACKGROUND: Metastasis to the breast from extramammary malignancies is rare.
  • CASE: A 35-year-old woman presented with bilaterally inflammatory breast involvement, 2 years after the diagnosis of stage IIIC epithelial ovarian cancer.
  • Neoplastic tissue was immunohistochemically positive using antibodies against OC125 and negative for gross cystic disease fluid protein-15 (BRST-2) and estrogen receptor in biopsy material in the breast.
  • Combination chemotherapy consisting of paclitaxel, cisplatin, and anthracycline was started.
  • She died 18 months after the breast metastasis.
  • CONCLUSION: Ovarian carcinoma usually presents with signs and symptoms related to the tumor burden within the abdominal cavity.
  • The finding of isolated, distant metastases such as breast involvement without intraabdominal disease is extremely rare.
  • Determining the origin of the primary tumor is important in directing the actual therapy.
  • [MeSH-major] Breast Neoplasms / secondary. Cystadenocarcinoma, Papillary / secondary. Ovarian Neoplasms / pathology


35. Shen J, Valero V, Buchholz TA, Singletary SE, Ames FC, Ross MI, Cristofanilli M, Babiera GV, Meric-Bernstam F, Feig B, Hunt KK, Kuerer HM: Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol; 2004 Sep;11(9):854-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy.
  • BACKGROUND: The presence of skin involvement has been accepted as a relative contraindication to breast preservation because it is believed to be associated with an increased local failure rate.
  • This study was conducted to assess the outcome of a carefully selected group of patients who presented with breast cancer involving the skin and who had breast conservation therapy (BCT) following neoadjuvant chemotherapy.
  • METHODS: Between 1987 and 1999, 33 patients with stage IIIB or IIIC breast cancer completed treatment consisting of four cycles of neoadjuvant chemotherapy, lumpectomy, radiation therapy, and consolidative chemotherapy.
  • RESULTS: Initial median tumor size was 7 cm.
  • Following chemotherapy, median pathologic tumor size was 2 cm.
  • At median follow-up time of 91 months in surviving patients, 26 patients (79%) were alive without evidence of disease.
  • The actuarial ipsilateral breast cancer recurrence rate was 6% at 5 years.
  • CONCLUSIONS: Patients who present with T4 breast cancer who experience tumor shrinkage and resolution of skin changes with neoadjuvant chemotherapy represent a select group of patients who can have BCT.
  • Mastectomy is not mandatory for all patients with breast cancer who present with skin involvement.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Mastectomy, Segmental. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2004 Oct;11(10):888-91 [15383420.001]
  • (PMID = 15313733.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Li B, Wu LY, Zhang WH, Li L, Ma SK, Liu LY: [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor]. Zhonghua Fu Chan Ke Za Zhi; 2004 May;39(5):334-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 11 cases of ovarian Setoli-Leydig cell tumor].
  • OBJECTIVE: To study the clinical characteristics, treatment and prognostic factors of ovarian Setoli-Leydig cell tumor.
  • METHODS: During 1962 - 2002, a total of 11 patients with Setoli-Leydig cell tumor were retrospectively analyzed.
  • Nine of the tumors were stage Ia, 1 was stage IIc and 1 was stage IIIc.
  • Two patients suffered from breast cancer.
  • And 5 patients with poorly differentiated or stage II-III tumors were subjected to postoperational chemotherapy.
  • CONCLUSIONS: Ovarian Setoli-Leydig cell tumor has good prognosis.
  • Surgery alone is a currently acceptable treatment for patients with well-differentiated early stage tumors.
  • For patients with poorly differentiated or advanced tumors, postoperational chemotherapy seems to be necessary.
  • Conservative surgery should be the treatment of choice in young patients who need future fertility.
  • [MeSH-major] Ovarian Neoplasms. Sertoli-Leydig Cell Tumor
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196418.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Gatek J, Kotoc J, Kotocová K, Katrusák J, Vázan P, Duben J, Hnátek L, Dudesek B: [Locoregional recurrences after conservative surgery in early breast cancer]. Rozhl Chir; 2010 Oct;89(10):604-11
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locoregional recurrences after conservative surgery in early breast cancer].
  • INTRODUCTION: Conservative surgery is considered as standard and alternative mastectomy in early stage breast cancer but number of local recurrence is higher.
  • MATERIALS AND METHODS: Local recurrences were evaluated in patients after conservative surgery in early breast cancer at department of surgery Atlas hospital in Zlin between January 2004 and December 2008.
  • T1-2 (only one T3) breast cancers were included in study.
  • Study guidelines required microscopic distance between resection line and tumor margin 5mm.
  • Radiotherapy and chemotherapy in additions to character of cancer followed surgery.
  • Stage of the tumor: 0 19x, I 101x, IIA 163x, IIB 33x, IIIA 5, IIIB 0, IIIC 9.
  • In breast local recurrence appeared in 5 (3.6%) patients and one had regional recurrence without in breast recurrence.
  • Clear margins after breast conserving surgery are very important factor in prevention local recurrence.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21374943.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


38. Kuru B, Bozgul M: The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma. Int J Radiat Oncol Biol Phys; 2006 Dec 1;66(5):1328-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of axillary lymph nodes removed in staging of node-positive breast carcinoma.
  • PURPOSE: Number of positive lymph nodes in the axilla and pathologic lymph node status (pN) have a great impact on staging according to the current American Joint Committee on Cancer staging system of breast carcinoma.
  • METHODS AND MATERIALS: The records of 798 consecutive invasive breast cancer patients with T1-3 tumors and positive axillary lymph nodes who underwent modified radical mastectomy between 1999 and 2005 in our hospital were reviewed.
  • The total number of removed nodes were grouped, and compared with the patient and tumor characteristics and the influence of the number of nodes removed on the staging was analyzed.
  • Although the proportion of Stage IIA and IIB decreased, the proportion of Stage IIIA and IIIC increased in patients with >20 nodes removed compared with those with 1-20 nodes removed.
  • CONCLUSIONS: In patients with axillary node-positive breast carcinoma, staging is highly influenced by total number of removed nodes.
  • Levels I-III axillary dissection with more than 20 axillary lymph nodes removed could lead to more effective adjuvant chemotherapy and increases substantially the proportion of patients to receive radiotherapy.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / surgery. Lymph Node Excision. Lymph Nodes / pathology. Neoplasm Staging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997505.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R: Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol; 2008 Dec;15(6):271-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual cancer burden in locally advanced breast cancer: a superior tool.
  • OBJECTIVES: Locally advanced breast cancer (LABC) poses a difficult clinical challenge with an overall poor long-term prognosis.
  • The strength of the association between tumour characteristics, treatment response, and outcome is not well defined.
  • In the present study, we attempted to gain further insight into LABC by reviewing tumour characteristics of patients treated with neoadjuvant chemotherapy and by studying the association of those characteristics with outcome.
  • We calculated the residual cancer burden (RCB) score obtained at surgery and attempted to study its correlation with event-free survival (EFS) and overall survival (OS).
  • RESULTS: Of the 45 study patients, 9% had stage IIB disease; 29%, stage IIIA; 51%, stage IIIB; and 11%, stage IIIC.
  • Inflammatory breast cancer (IBC) was found in 16%.
  • It appears to be a better predictor than pCR of outcome following neoadjuvant chemotherapy in LABC.
  • A continual quest for reliable predictive and correlative prognostic markers, and for better surrogate endpoints for outcome, is essential to advance our understanding of LABC and to improve treatment outcomes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4414-22 [17785706.001]
  • [Cites] J Cell Biol. 1993 Nov;123(3):513-22 [8227122.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1005-12 [17047649.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):171-7 [16601438.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1037-44 [16505422.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7350-60 [16145060.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3676-85 [15738535.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] N Engl J Med. 1998 Oct 1;339(14):974-84 [9753714.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):1969-75 [8562150.001]
  • [Cites] J Clin Oncol. 1988 Jul;6(7):1076-87 [2856862.001]
  • [Cites] Cancer. 1988 Dec 15;62(12):2507-16 [3056604.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Dec;18(12):1315-20 [6891930.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4067-74 [15483018.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1304-10 [11870173.001]
  • [Cites] Eur J Cancer. 2007 May;43(7):1153-60 [17398088.001]
  • (PMID = 19079627.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2601022
  • [Keywords] NOTNLM ; Breast cancer / endpoints / locally advanced disease / pathology / residual disease
  •  go-up   go-down


40. Nishimura N, Hachisuga T, Saito T, Kawarabayashi T: Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients. Int J Gynecol Cancer; 2001 Jul-Aug;11(4):272-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsequent endometrial carcinoma with adjuvant tamoxifen treatment in Japanese breast cancer patients.
  • This study aimed to detail the clinicopathologic features of endometrial carcinomas that developed in Japanese patients receiving adjuvant tamoxifen treatment for breast cancer patients.
  • Ten endometrial carcinomas in tamoxifen-treated breast cancer patients were collected from two medical centers.
  • The endometrial carcinomas included two stage Ia, four stage Ib, two stage Ic and two stage IIIc.
  • The tumor was limited to the endometrium in two cases.
  • The cell types comprised nine endometrioid adenocarcinomas and one serous carcinoma.
  • Two patients with retroperitoneal lymph node metastases died of endometrial cancer.
  • One patient developed a contralateral breast cancer during tamoxifen treatment.
  • No patient died of breast cancer.
  • We did not demonstrate a higher frequency of either high-grade tumors or unfavorable histologic subtypes in tamoxifen-treated Japanese breast cancer patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / etiology. Tamoxifen / adverse effects
  • [MeSH-minor] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Aged. Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Japan. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11520364.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


41. Iqbal J, Bano K, Saeed A, Akram M, Aziz Z: Survival of women with locally advanced breast cancer at a teaching hospital in Lahore. J Pak Med Assoc; 2010 Sep;60(9):721-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of women with locally advanced breast cancer at a teaching hospital in Lahore.
  • OBJECTIVES: To correlate the clinical features of women presenting with locally advanced breast cancer with event-free survival (EFS) and overall survival (OS) and to evaluate the patterns of relapse.
  • METHODS: A total of 200 patients presenting consecutively over 9 years with Stage III breast cancer were evaluated for age, socio-economic status (SES), tumour size and grade, number of involved lymph nodes, stage III sub-categories, estrogen and progesterone receptor (ER/PR) status, treatment profiles and responses, and sites of relapse.
  • Eighty women had extensive nodal involvement (N2 and N3), and 86 had Stage IIIA tumours.
  • Chemotherapy was given to 44 patients before surgery and one of these patients achieved pathological complete response.
  • No patient in stage IIIC was alive at 10 years.
  • CONCLUSIONS: Locally advance breast cancer at our centre is associated with poor survival, and most patients relapsed by 5 years.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Hospitals, Teaching / statistics & numerical data. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Neoplasm Staging. Pakistan / epidemiology. Prognosis. Recurrence. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pak Med Assoc. 2010 Dec;60(12):1067-8; author reply 1068-9 [21381567.001]
  • (PMID = 21381576.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


42. Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, Yatabe Y, Imai T, Ohashi Y: Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast; 2010 Oct;19(5):370-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer.
  • We conducted a phase II study using docetaxel and trastuzumab as preoperative systemic treatment for locally advanced HER-2-overexpressing breast cancer (stage IIIB or IIIC) to evaluate the efficacy and safety, and to perform a subset analysis based on tumor biomarkers.
  • Patients received 4 mg/kg trastuzumab on day 1, followed by weekly treatments of 2mg/kg, in addition to 75 mg/m(2) docetaxel every 3 weeks for 4 cycles before surgery.
  • The median age was 54 years and median tumor size was 63 mm.
  • The combination of docetaxel and trastuzumab produced highly favorable clinical and pathological responses for locally advanced HER-2-overexpressing breast cancer.
  • Subgroup analysis suggests that ER/PgR negative tumors might be associated with pathological response in locally advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / metabolism. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoplasm Staging. Receptor, ErbB-2 / metabolism. Taxoids / administration & dosage. Taxoids / adverse effects. Trastuzumab. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20472435.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down






Advertisement